In breast cancer, reduction in WNT signaling by addition of secreted negative regulators of the pathways, like DKK1 or SFRP1 can promote reduction in migration and invasion, whereas inhibition of SFRP1, and thus elevated WNT signaling, can support an EMT phenotype and sensitize to TGFβ‐induced EMT (Gauger et al, 2011; Scheel et al, 2011). This evidence concerns the gene SFRP1 and breast cancer.